Neovascular Age-related Macular Degeneration Treatment Market Snapshot (2023 to 2033)

The global neovascular age-related macular degeneration treatment market is expected to garner a market value of USD 3 billion in 2023 and is expected to accumulate a market value of USD 4.89 billion by registering a CAGR of 5% in the forecast period 2023 to 2033.

The market for neovascular age-related macular degeneration treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.

The Neovascular Age-related Macular Degeneration Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The market is expected to grow significantly in the coming years due to the increasing prevalence of the condition worldwide. Neovascular age-related macular degeneration is a serious eye condition that affects older adults and can lead to vision loss. The treatment of nAMD typically involves medications that are injected into the eye to stop the growth of abnormal blood vessels in the retina. These medications are known as anti-VEGF drugs.

Report Attribute Details
Expected Market Value (2023) USD 3 billion
Anticipated Forecast Value (2033) USD 4.89 billion
Projected Growth Rate (2023 to 2033) 5% CAGR

Exclusive Offer: 30% Off on Regional Reports

Get a free sample report and customize your regions for a 30% discount on your regional report!

2018 to 2022 Neovascular Age-related Macular Degeneration Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for Neovascular Age-related Macular Degeneration Treatment reflected a value of 3.5% during the historical period, 2018 to 2022.

The neovascular age-related macular degeneration treatment market has been growing rapidly in recent years due to the increasing prevalence of nAMD and the availability of effective drugs for its treatment. The market is expected to continue growing in the coming years as the aging population continues to grow.

The key players in the neovascular age-related macular degeneration treatment market include pharmaceutical companies such as Roche, Novartis, Regeneron, and Bayer. These companies are investing heavily in research and development to bring new and improved drugs to market for the treatment of nAMD. In addition to anti-VEGF drugs, other treatments for nAMD are also being developed, including gene therapy and sustained-release drug delivery systems. These new treatments have the potential to improve patient outcomes and reduce the need for frequent injections.

Moreover, strategic collaborations, mergers and acquisitions, and product innovations are expected to further drive the growth of the Neovascular Age-related Macular Degeneration Treatment market. Key players in the market are investing in R&D activities to develop new treatment options and improve the efficacy of existing ones.

The market offers growth opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers. Overall, the market for neovascular age-related macular degeneration treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Neovascular Age-related Macular Degeneration Treatment Market?

Growing Awareness along with increasing prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth

The neovascular age-related macular degeneration (nAMD) treatment market has been experiencing significant growth in recent years and is expected to continue growing in the coming years. Several factors are driving this growth, including:

  • Increasing prevalence of nAMD: As the global population ages, the prevalence of nAMD is increasing. According to the World Health Organization, the number of people aged 65 years and older is projected to triple by 2050, which will lead to an increase in the number of nAMD cases.
  • Advancements in treatment options: The introduction of anti-VEGF drugs has revolutionized the treatment of nAMD. These drugs have been shown to be highly effective in halting the growth of abnormal blood vessels in the retina, which can prevent vision loss in patients with nAMD.
  • Rising healthcare expenditure: As healthcare expenditure continues to rise, more resources are being allocated towards the development and adoption of new nAMD treatments. This has led to an increase in research and development activities, as well as greater patient access to new and innovative treatments.

Get Brochure on Email

Almost 80% of our clients request uniquely tailored intelligence.

What are the Challenges Faced by the Neovascular Age-related Macular Degeneration Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The cost of nAMD treatment with anti-VEGF drugs can be very high, and this can limit patient access to these treatments. Some patients may not be able to afford the cost of treatment, while others may face limitations in their insurance coverage.

Moreover, Anti-VEGF drugs are typically administered through injections directly into the eye, which can be uncomfortable and inconvenient for patients. Additionally, these injections need to be given on a regular basis, which can be challenging for patients who have difficulty traveling to clinics or for those who may be homebound.

Region-Wise Insights

How is the Neovascular Age-related Macular Degeneration Treatment Market Turning Out in the South & East Asia Regions?

Increasing awareness and diagnosis of the condition Shaping Landscape in South & East Asia

The neovascular age-related macular degeneration (nAMD) treatment market is turning out to be promising in the South & East Asia region. The prevalence of nAMD is increasing in the region due to aging populations, changing lifestyles, and increasing prevalence of diabetes.

Several pharmaceutical companies have been focusing on expanding their market presence in the region by investing in research and development, strategic partnerships, and collaborations. For example, Novartis and Roche have been leading players in the nAMD treatment market in the region, and have been expanding their product portfolios and conducting clinical trials for new treatments.

In addition, the availability of biosimilars of anti-VEGF drugs has increased in the region, which has made treatment more affordable for patients. The use of biosimilars has also increased competition in the market, leading to more affordable treatment options. However, challenges remain in the region, including limited access to specialized ophthalmologists, inadequate healthcare infrastructure in some areas, and low awareness of nAMD and its treatment options among patients and healthcare providers.

Overall, the nAMD treatment market in South & East Asia is expected to continue growing in the coming years, driven by factors such as increasing patient awareness, expanding healthcare infrastructure, and the introduction of new treatments.

What are the Factors Boosting the Market for Neovascular Age-related Macular Degeneration Treatment in North America?

Increasing Focus on technological advancements driving demand for Neovascular Age-related Macular Degeneration Treatment in North America

The aging population in North America is contributing to the increasing prevalence of nAMD. According to the American Academy of Ophthalmology, more than 10 million Americans are affected by AMD, with nAMD accounting for a significant portion of these cases.

North America is at the forefront of research and development of new nAMD treatments, and the availability of advanced treatment options such as anti-VEGF drugs has contributed to the growth of the market. Additionally, the introduction of gene therapy and sustained-release drug delivery systems has further expanded treatment options.

The strong healthcare infrastructure in North America has contributed to the growth of the nAMD treatment market, with access to specialized ophthalmologists, well-equipped healthcare facilities, and advanced diagnostic and treatment technologies. The increasing awareness of nAMD and its treatment options among patients and healthcare providers has contributed to the growth of the market. Patients are now seeking earlier diagnosis and treatment, which has increased the demand for effective nAMD treatments.

Check Free Sample Report & Save 40%!

Select your niche segments and personalize your insights for smart savings. Cut costs now!

Category-Wise Insights

By Disease type, Which Segment is Likely to Account for a Significant Share?

Wet AMD segment to hold a significant share and push market growth

Wet AMD is likely to account for a significant share in the Neovascular Age-related Macular Degeneration Treatment market is Wet AMD. Wet AMD is a more severe form of the disease and can progress rapidly, causing severe vision loss or blindness if left untreated.

This has led to a higher demand for treatments that can effectively manage the condition, such as anti-vascular endothelial growth factor (anti-VEGF) drugs. These drugs are used to block the growth of abnormal blood vessels and reduce fluid leakage in the retina, slowing down the progression of the disease and improving vision.

By State of Disease, Which Segment is Likely to Account for a Significant Share?

Late-stage AMD segment to hold a significant share and push market growth

Among the different stages of AMD, the Late-stage AMD segment is likely to account for a significant share in the neovascular age-related macular degeneration treatment market.

Late-stage AMD includes both wet AMD and geographic atrophy, which are advanced forms of the disease that can cause severe vision loss or blindness if left untreated. As a result, there is a higher demand for effective treatments for late-stage AMD, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, which can help slow down the progression of the disease and improve vision.

Market Competition

Key players in the market include companies such as Competition Deep Dive, Competition Deep Dive, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc., ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc.

GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., Bayer AG, Rxi Pharmaceuticals Inc. along with healthcare providers and technology companies among other global players.

  • Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant was granted FDA approval on October 22, 2021. This approval is for the treatment of wet or neovascular age-related macular degeneration (AMD) in individuals who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Wet AMD is a leading cause of blindness in people aged 60 and older and affects approximately 1.1 million people in the United States.

Report Scope

Report Attribute Details
Market Value in 2023 USD 3 billion
Market Value in 2033 USD 4.89 billion
Growth Rate CAGR of 5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered

Disease Type, Drug Type, Age group, Gender, Stage of Disease, Distribution Channel, Region

Regions Covered

North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa

Key Countries Profiled

United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel

Key Companies Profiled F. Hoffmann- La Roche AG; Bausch + Lomb; Novartis AG; Pfizer Inc.; Allergan Plc.; Acucela Inc.; Santen Pharmaceuticals Co.; Ophthotech Corporation; Alimera Sciences Inc.; GSK plc.; Regeneron Pharmaceuticals Inc.; Bayer AG; RXi Pharmaceuticals Inc.
Customization Available Upon Request
Table of Content
  • 1. Executive Summary 
  • 2. Market Overview
  • 3. Market Background
  • 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
  • 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
    • 5.1. Ranibizumab
    • 5.2. Aflibercept
    • 5.3. Bevacizumab
    • 5.4. Brolucizumab
    • 5.5. Faricimab
  • 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
    • 6.1. Dry AMD
    • 6.2. Wet AMD
  • 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group
    • 7.1. Less Than 60
    • 7.2. Between 60 to 80
    • 7.3. More Than 80
  • 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender
    • 8.1. Male
    • 8.2. Female
  • 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage of Disease
    • 9.1. Early-stage AMD
    • 9.2. Intermediate AMD
    • 9.3. Late-stage AMD
  • 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    • 10.1. Hospital Pharmacy
    • 10.2. Specialty Pharmacy
    • 10.3. Online Pharmacy
  • 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    • 11.1. North America
    • 11.2. Latin America
    • 11.3. Europe
    • 11.4. South Asia
    • 11.5. East Asia
    • 11.6. Oceania
    • 11.7. MEA
  • 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 18. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 19. Key Countries Market Analysis
  • 20. Market Structure Analysis
  • 21. Competition Analysis
    • 21.1. F.Hoffmann-La Roche AG
    • 21.2. Bausch + Lomb
    • 21.3. Novartis AG
    • 21.4. Pfizer Inc.
    • 21.5. Allergan Plc.
    • 21.6. Acucela Inc.
    • 21.7. Santen Pharmaceuticals Co.
    • 21.8. Ophthotech Corporation
    • 21.9. Alimera Sciences Inc.
    • 21.10. GSK plc.
    • 21.11. Regeneron Pharmaceuticals Inc.
    • 21.12. Bayer AG
    • 21.13. RXi Pharmaceuticals Inc.
  • 22. Assumptions & Acronyms Used
  • 23. Research Methodology

Key Segments Profiled in the Neovascular Age-related Macular Degeneration Treatment Industry Survey

Drug Type:

  • Ranibizumab
  • Aflibercept
  • Bevacizumab
  • Brolucizumab
  • Faricimab

Disease Type:

  • Dry AMD
  • Wet AMD

Age Group:

  • Less than 60
  • Between 60 to 80
  • More than 80

Gender:

  • Male
  • Female

Stage of Disease:

  • Early-stage AMD
  • Intermediate AMD
  • Late-stage AMD

Distribution Channel:

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Neovascular Age-related Macular Degeneration Treatment Market Size?

The neovascular age-related macular degeneration treatment market size reaches USD 3 billion in 2023.

What Size is the Neovascular Age-related Macular Degeneration Treatment Market Expected to Reach by 2033?

The market is set to surge at a 5% CAGR, reaching a valuation of USD 4.89 billion by 2033.

How has the Market Evolved During the Historical Period?

The market witnessed a 3.5% CAGR between 2018 and 2022.

Which Country Shows Promising Potential for Neovascular Age-related Macular Degeneration Treatment?

The United States exhibits promising potential for neovascular age-related macular degeneration treatment due to its advanced healthcare infrastructure.

Which Disease Type Segment Generates the Maximum Revenue in the Market?

The Wet AMD segment demonstrates significant expansion in the neovascular age-related macular degeneration treatment market.

Recommendations

Vision Screener Market
Estimated Size, 2024 USD 636.2 million
Projected Size, 2034 USD 1.2 billion
Value-based CAGR (2024 to 2034) 5.2%
Vision Care Market
Market Valuation (2023) USD 89,596 million
Market Projected Size (2033) USD 1,78,930.9 million
Market Anticipated CAGR (2023 to 2033) 7.2%
Age Related Vision Dysfunction Market
Expected Market Value (2023) USD 90 Billion
Anticipated Forecast Value (2033) USD 130 Billion
Projected Growth Rate (2023 to 2033) 3.7% CAGR
Age Related Molecular Degeneration Market
Expected Market Value (2023) USD 11.28 Million
Projected Forecast Value (2033) USD 22.19 Million
Growth Rate (2023 to 2033) 7% CAGR

Explore Therapy Area Insights

View Reports
Trusted By
Future Market Insights

Neovascular Age-related Macular Degeneration Treatment Market

Schedule a Call